Online inquiry

IVTScrip™ mRNA-Anti-CD3E&MS4A1, REGN-1979(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ13866MR)

This product GTTS-WQ13866MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets CD3E&MS4A1 gene. The antibody can be applied in Chronic lymphocytic leukemia (CLL), Non-Hodgkin's lymphoma (NHL) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_000733.4; NM_021950.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 916; 931
UniProt ID P07766; P11836
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD3E&MS4A1, REGN-1979(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ13866MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ130MR IVTScrip™ mRNA-Anti-EGFR, 11F8(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA 11F8
GTTS-WQ1978MR IVTScrip™ mRNA-Anti-SLITRK6, AGS-15E(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA AGS-15E
GTTS-WQ15171MR IVTScrip™ mRNA-Anti-CD6, T1h(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA T1h
GTTS-WQ2919MR IVTScrip™ mRNA-Anti-ERBB3, AMG888(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA AMG888
GTTS-WQ11383MR IVTScrip™ mRNA-Anti-IGF, MEDI-573(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA MEDI-573
GTTS-WQ14142MR IVTScrip™ mRNA-Anti-PCSK9, aPCSK927(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA aPCSK927
GTTS-WQ1453MR IVTScrip™ mRNA-Anti-CD22, ACD22-VCMMAE(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ACD22-VCMMAE
GTTS-WQ10632MR IVTScrip™ mRNA-Anti-MAPT, LY-3303560(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA LY-3303560
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW